Bayer owns rights to R-ketoprofen in development with Sepracor.
BAYER OWNS RIGHTS TO R-KETOPROFEN IN DEVELOPMENT WITH SEPRACOR and paid the Boulder-based company $1 mil. in licensing fees in late 1994, according to a secondary stock registration document filed by Sepracor with the Securities & Exchange Commission June 9. Sepracor Chief Financial Officer David Southwell misspoke at a May 11 securities analysts conference sponsored by Dillon, Reed when he said the company was working with SmithKline Beecham on the R-ketoprofen form of the analgesic.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth